H.C. Wainwright Issues a Buy Rating on Akebia Therapeutics

By Austin Angelo

In a report released today, Ed Arce from H.C. Wainwright assigned a Buy rating to Akebia Therapeutics (NASDAQ: AKBA), with a price target of $24. The company’s shares closed yesterday at $14.24.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 19.9% and a 43.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Neptune Technologies & Bioresources Inc, Aviragen Therapeutics Inc, and Collegium Pharmaceutical.

Currently, the analyst consensus on Akebia Therapeutics is Strong Buy and the average price target is $21.50, representing a 51.0% upside.

In a report issued on November 9, Mizuho Securities also assigned a Buy rating to the stock with a $24 price target.

The company has a one-year high of $20.25 and a one-year low of $7.78. Currently, Akebia Therapeutics has an average volume of 402K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Akebia Therapeutics, Inc. is a biopharmaceutical company which engages in the development of novel proprietary therapeutics based on hypoxia-inducible factor and biology. It also includes the development and commercialization of drugs for the treatment of renal and metabolic disorders.